Supernus Stock Based Compensation from 2010 to 2025

SUPN Stock

USD 37.49 0.57 1.50%

Supernus Pharmaceuticals Stock Based Compensation yearly trend continues to be very stable with very little volatility. Stock Based Compensation is likely to grow to about 32.3 M this year. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2009-12-31

Previous Quarter

6.6 M

Current Value

7.7 M

Quarterly Volatility

2.3 M

Credit Downgrade

Yuan Drop

Covid

Check Supernus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Supernus Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 102.5 M, Interest Expense of 2.6 M or Total Revenue of 733.6 M, as well as many indicators such as Price To Sales Ratio of 2.84, Dividend Yield of 0.0 or PTB Ratio of 1.51. Supernus financial statements analysis is a perfect complement when working with Supernus Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Supernus Pharmaceuticals Correlation against competitors.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

Latest Supernus Pharmaceuticals' Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Supernus Pharmaceuticals over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Supernus Pharmaceuticals' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Supernus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Supernus Stock Based Compensation Regression Statistics

	Arithmetic Mean	11,979,590
	Coefficient Of Variation	91.39
	Mean Deviation	9,108,901
	Median	11,291,000
	Standard Deviation	10,947,799
	Sample Variance	119.9T
	Range	32.4M
	R-Value	0.97
	Mean Square Error	8.2T
	R-Squared	0.94
	Slope	2,224,516
	Total Sum of Squares	1797.8T

Supernus Stock Based Compensation History

	2025	32.3 M
	2024	30.8 M
	2023	26.8 M
	2022	17.6 M
	2021	17.9 M
	2020	16.6 M
	2019	14.8 M

Other Fundumenentals of Supernus Pharmaceuticals

Stock Based Compensation To Revenue

Supernus Pharmaceuticals Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Current Deferred Revenue	Long Term Debt	Short Term Debt	Property Plant Equipment	Net Tangible Assets	Good Will	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.96	0.63	0.94	-0.24	0.98	0.87	0.9	0.94	0.88	0.64	0.55	0.96	0.28	0.92	0.14	0.91	0.92	0.91	0.93	0.35	0.9	0.99	0.57	0.57
Total Stockholder Equity	0.96		0.43	0.98	-0.36	0.98	0.85	0.74	0.84	0.91	0.64	0.36	0.95	0.21	0.95	0.06	0.96	0.92	0.89	0.9	0.19	0.89	0.93	0.47	0.74
Net Debt	0.63	0.43		0.44	0.2	0.5	0.67	0.85	0.74	0.41	0.25	0.69	0.57	0.54	0.41	0.25	0.35	0.48	0.51	0.56	0.54	0.48	0.71	0.38	-0.07
Retained Earnings	0.94	0.98	0.44		-0.35	0.95	0.85	0.72	0.82	0.93	0.49	0.33	0.94	0.23	0.96	-0.02	0.97	0.89	0.81	0.89	0.11	0.85	0.92	0.4	0.74
Accounts Payable	-0.24	-0.36	0.2	-0.35		-0.36	-0.14	-0.01	-0.15	-0.26	-0.18	0.27	-0.31	0.23	-0.28	-0.04	-0.35	-0.3	-0.33	-0.18	0.05	-0.31	-0.18	-0.2	-0.44
Net Receivables	0.98	0.98	0.5	0.95	-0.36		0.86	0.81	0.89	0.9	0.67	0.38	0.94	0.28	0.93	0.09	0.95	0.94	0.92	0.9	0.24	0.91	0.94	0.49	0.65
Short Term Investments	0.87	0.85	0.67	0.85	-0.14	0.86		0.76	0.86	0.77	0.57	0.31	0.86	0.57	0.78	0.12	0.8	0.8	0.77	0.77	0.25	0.78	0.89	0.26	0.54
Total Liab	0.9	0.74	0.85	0.72	-0.01	0.81	0.76		0.95	0.7	0.56	0.75	0.82	0.36	0.72	0.23	0.68	0.77	0.82	0.82	0.53	0.76	0.92	0.64	0.23
Total Current Assets	0.94	0.84	0.74	0.82	-0.15	0.89	0.86	0.95		0.75	0.69	0.59	0.88	0.39	0.78	0.25	0.78	0.86	0.91	0.83	0.46	0.85	0.95	0.58	0.42
Intangible Assets	0.88	0.91	0.41	0.93	-0.26	0.9	0.77	0.7	0.75		0.47	0.3	0.83	0.29	0.98	-0.32	0.98	0.78	0.75	0.9	-0.13	0.72	0.86	0.26	0.68
Common Stock	0.64	0.64	0.25	0.49	-0.18	0.67	0.57	0.56	0.69	0.47		0.31	0.56	0.21	0.52	0.28	0.55	0.64	0.86	0.55	0.36	0.63	0.58	0.39	0.38
Current Deferred Revenue	0.55	0.36	0.69	0.33	0.27	0.38	0.31	0.75	0.59	0.3	0.31		0.46	0.05	0.39	0.37	0.24	0.42	0.49	0.48	0.67	0.42	0.59	0.65	-0.1
Long Term Debt	0.96	0.95	0.57	0.94	-0.31	0.94	0.86	0.82	0.88	0.83	0.56	0.46		0.12	0.88	0.19	0.87	0.91	0.87	0.92	0.37	0.88	0.96	0.63	0.64
Short Term Debt	0.28	0.21	0.54	0.23	0.23	0.28	0.57	0.36	0.39	0.29	0.21	0.05	0.12		0.21	-0.1	0.27	0.21	0.2	0.12	-0.07	0.19	0.3	-0.41	-0.03
Property Plant Equipment	0.92	0.95	0.41	0.96	-0.28	0.93	0.78	0.72	0.78	0.98	0.52	0.39	0.88	0.21		-0.19	0.98	0.83	0.8	0.92	0.0	0.78	0.9	0.37	0.71
Net Tangible Assets	0.14	0.06	0.25	-0.02	-0.04	0.09	0.12	0.23	0.25	-0.32	0.28	0.37	0.19	-0.1	-0.19		-0.19	0.26	0.25	-0.08	0.91	0.33	0.14	0.57	-0.15
Good Will	0.91	0.96	0.35	0.97	-0.35	0.95	0.8	0.68	0.78	0.98	0.55	0.24	0.87	0.27	0.98	-0.19		0.86	0.81	0.89	-0.05	0.82	0.87	0.3	0.74
Long Term Debt Total	0.92	0.92	0.48	0.89	-0.3	0.94	0.8	0.77	0.86	0.78	0.64	0.42	0.91	0.21	0.83	0.26	0.86		0.88	0.84	0.39	1.0	0.88	0.57	0.6
Capital Surpluse	0.91	0.89	0.51	0.81	-0.33	0.92	0.77	0.82	0.91	0.75	0.86	0.49	0.87	0.2	0.8	0.25	0.81	0.88		0.84	0.42	0.86	0.88	0.59	0.55
Deferred Long Term Liab	0.93	0.9	0.56	0.89	-0.18	0.9	0.77	0.82	0.83	0.9	0.55	0.48	0.92	0.12	0.92	-0.08	0.89	0.84	0.84		0.19	0.8	0.92	0.53	0.58
Long Term Investments	0.35	0.19	0.54	0.11	0.05	0.24	0.25	0.53	0.46	-0.13	0.36	0.67	0.37	-0.07	0.0	0.91	-0.05	0.39	0.42	0.19		0.44	0.37	0.75	-0.19
Short Long Term Debt	0.9	0.89	0.48	0.85	-0.31	0.91	0.78	0.76	0.85	0.72	0.63	0.42	0.88	0.19	0.78	0.33	0.82	1.0	0.86	0.8	0.44		0.85	0.59	0.56
Net Invested Capital	0.99	0.93	0.71	0.92	-0.18	0.94	0.89	0.92	0.95	0.86	0.58	0.59	0.96	0.3	0.9	0.14	0.87	0.88	0.88	0.92	0.37	0.85		0.58	0.54
Net Working Capital	0.57	0.47	0.38	0.4	-0.2	0.49	0.26	0.64	0.58	0.26	0.39	0.65	0.63	-0.41	0.37	0.57	0.3	0.57	0.59	0.53	0.75	0.59	0.58		0.11
Capital Stock	0.57	0.74	-0.07	0.74	-0.44	0.65	0.54	0.23	0.42	0.68	0.38	-0.1	0.64	-0.03	0.71	-0.15	0.74	0.6	0.55	0.58	-0.19	0.56	0.54	0.11

Click cells to compare fundamentals

About Supernus Pharmaceuticals Financial Statements

Supernus Pharmaceuticals investors utilize fundamental indicators, such as Stock Based Compensation, to predict how Supernus Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Stock Based Compensation	30.8 M	32.3 M
Stock Based Compensation To Revenue	0.05	0.05

Pair Trading with Supernus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Supernus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Supernus Stock

0.81

BMY

Bristol Myers Squibb

Pair Corr

Moving against Supernus Stock

0.76	PFE	Pfizer Inc Fiscal Year End 4th of February 2025	Pair Corr
0.73	LLY	Eli Lilly	Pair Corr
0.73	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.71	JNJ	Johnson Johnson Sell-off Trend	Pair Corr
0.64	UPC	Universe Pharmaceuticals	Pair Corr

The ability to find closely correlated positions to Supernus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Supernus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Supernus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Supernus Pharmaceuticals to buy it.

The correlation of Supernus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Supernus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Supernus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Supernus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:

How To Invest In Supernus

Details

Is Supernus Stock a good investment?

Details

What is Supernus Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Supernus Pharmaceuticals Correlation against competitors.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.99)

Earnings Share

1.05

Revenue Per Share

11.877

Quarterly Revenue Growth

0.142

Return On Assets

0.0289

The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Supernus Stock Based Compensation from 2010 to 2025

Latest Supernus Pharmaceuticals' Stock Based Compensation Growth Pattern

Supernus Stock Based Compensation Regression Statistics

Supernus Stock Based Compensation History

Other Fundumenentals of Supernus Pharmaceuticals

Supernus Pharmaceuticals Stock Based Compensation component correlations

About Supernus Pharmaceuticals Financial Statements

Pair Trading with Supernus Pharmaceuticals

Moving together with Supernus Stock

Moving against Supernus Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY